SCHEMBL30983423

SCHEMBL30983423

CN1CCN(CCOc2ccc(-c3nc4c(OC5(C)CC5)ncnc4n3Cc3ccccc3Cl)c(Cl)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 6/20 0.41
▸ DRD2 P14416 2/20 0.40
▸ CNR1 P21554 5/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ SRC P12931 2/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KCNH2 Q12809 2/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983822 0.92 DRD2 (0.42) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983538 0.91 HRH4 (0.39) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983511 0.90 HRH4 (0.41) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983415 0.90 HRH4 (0.42) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983520 0.89 HRH4 (0.42) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983428 0.88 KMT2A (0.43) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983571 0.88 DRD2 (0.41) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983483 0.87 TLR7 (0.40) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983816 0.87 HRH4 (0.40) HRH4DRD2CNR1KDM4EALDH1A1
SCHEMBL30983478 0.85 DRD2 (0.41) HRH4DRD2KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HRH4 4696/4885DRD2 3087/4885CNR1 4278/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HRH4 4696/4885DRD2 3087/4885CNR1 4278/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HRH4 4696/4885DRD2 3087/4885CNR1 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback